The Effect of MMP-2 (-1306 C/T) Gene Variation in the Development of Ischemic Stroke
Abstract views: 474
/ 
PDF downloads: 111
DOI:
https://doi.org/10.5281/zenodo.7388026Keywords:
Ischemicstroke, MMP-2 gene, MMP-2 (-1306 C/T) gene variation, PCR, RFLPAbstract
The aim of this study is to determine the role of MMP-2 (-1306 C/T) gene variation in the development of ischemic stroke. Our study was carried out with 93 ischemic stroke patients and 94 healthy controls. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods were applied to determine the genotype distributions of MMP-2 (-1306 C/T) gene variation. Although the significant difference was not determined between ischemic stroke patients and healthy control groups in terms of age and alcohol parameters in our study (p>0.05), the significant difference was determined between these groups in terms of smoking, cerebrovascular disease history, hypertension, diabetes mellitus and heart disease parameters. Although CT heterozygous genotype of MMP-2 (-1306 C/T) gene variation was determined higher in ischemic stroke patient group compared to healthy controls, the significant difference was not detected between patient and control groups in terms of MMP-2 (-1306 C/T) gene variation genotype distributions. In addition, TT homozygous genotype of MMP-2 (-1306 C/T) gene variation was not observed in ischemic stroke patient group and healthy control group. In conclusion, MMP-2 (-1306 C/T) gene variation was not identified as a genetic risk factor for the development of ischemic stroke in the Thrace population of Turkey. Comprehensive studies with larger populations are needed to determine the relationship between MMP-2 (-1306 C/T) gene variation and the development of ischemic stroke.
References
Brouns, R., Wauters, A., De Surgeloose, D., Mariën, P., De Deyn, P.P. (2011). Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur Neurol, 65(1), 23-31.
Chang, J.J., Stanfill, A., Pourmotabbed, T. (2016). The Role of Matrix Metalloproteinase Polymorphisms in Ischemic Stroke. Int J Mol Sci, 17(8), 1323.
Chen, L., Yang, Q., Ding, R., Liu, D., Chen, Z. (2018). Carotid thickness and atherosclerotic plaque stability, serum inflammation, serum MMP-2 and MMP-9 were associated with acute cerebral infarction. Exp Ther Med, 16(6), 5253-5257.
Daskalopoulou, S.S., Daskalopoulos, M.E., Perrea, D., Nicolaides, A.N., Liapis, C.D. (2007). Carotid artery atherosclerosis: what is the evidence for drug action? Curr Pharm Des, 13(11), 1141-59.
Guo, T., Hao, H., Zhou, L., Zhou, F., Yu, D. (2017). Association of SNPs in the TIMP-2 gene and large artery atherosclerotic stroke in southern Chinese Han population. Oncotarget, 9(4), 4698-4706.
Halder, A.K., Saha, A., Jha, T. (2013). Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors. J Pharm Pharmacol, 65(10), 1541-54.
Han, S.W., Kim, S.H., Lee, J.Y., Chu, C.K., Yang, J.H., Shin, H.Y.,…,Heo, J.H. (2007). A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol, 57(2), 96-102.
Jacob-Ferreira, A.L., Schulz, R. (2013). Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart. Arch Biochem Biophys, 540(1-2), 82-93.
Kolb, B., Saber, H., Fadel, H., Rajah, G. (2019). The endocannabinoid system and stroke: A focused review. Brain Circ, 5(1), 1-7.
Li, Y., Ouyang, Q.R., Li, J., Chen, X.R., Li, L.L., Xu, L., Yu, M. (2021). Correlation between matrix metalloproteinase-2 polymorphisms and first and recurrent atherosclerotic ischemic stroke events: a case-control study. J Int Med Res, 49(6), 3000605211022967.
Lin, H.F., Hsi, E., Huang, L.C., Liao, Y.C., Juo, S.H., Lin, R.T. (2017). Methylation in the matrix metalloproteinase-2 gene is associated with cerebral ischemic stroke. J Investig Med, 65(4), 794-799.
Liu, L., Chen, W., Zhou, H., Duan, W., Li, S., Huo, X.,…,Wang, Y. (2020). Chinese Stroke Association Stroke Council Guideline Writing Committee. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases. Stroke Vasc Neurol, 5(2), 159-176.
Mukherjee, D., Patil, C.G. (2011). Epidemiology and the global burden of stroke. World Neurosurg, 76, S85-S90.
Niu, F., Wei, B., Yan, M., Li, J., Ouyang, Y., Jin, T. (2018). Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population. Medicine (Baltimore), 97(39), e12302.
Sternlicht, M.D., Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 17, 463-516.
Wågsäter, D., Zhu, C., Björkegren, J., Skogsberg, J., Eriksson, P. (2011). MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med, 28(2), 247-53.
Xu, L., Rx, Z., Q, L. (2016). Association between MMP-2 gene polymorphism and atherosclerotic cerebral infarction. Adv Anat Sci, 22, 273-275.
Zhang, L., Ren, R., Mu, S. (2016). The correlation of MMP-2 polymorphisms and stroke. Int J Clin Exp Med, 9(2), 4460-4466.
Zhao, J.H., Xu, Y.M., Xing, H.X., Su, L.L., Tao, S.B., Tian, X.J.,…,Ji, S.B. (2016). Associations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarction. Genet Mol Res, 14(4), 19418-24.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 